What CMS is changing—and why
CMS's July 16 memorandum says state survey agencies may use a risk-based version of the Long-Term Care Survey Process at eligible nursing homes beginning September 8, 2026. It remains a standard recertification survey—not a replacement for complaint surveys—but uses a smaller resident sample, fewer surveyors and activities, and roughly half the time. Every required area still receives a streamlined review.
CMS frames the policy as a capacity decision: state agencies face more complaint work while the federal survey budget has been flat since 2015. The agency says a pilot across 22 states and more than 100 facilities produced findings comparable to the traditional process. That is CMS's assessment; the memo does not publish enough study detail to treat it as proof that every defect is equally likely to surface.
A five-star rating is only the first gate
CMS estimates that about 12% of nursing homes will initially qualify. Its 11 criteria extend well beyond a five-star overall rating: they address staffing rating, serious citations, staffing and MDS audits, health-inspection performance, certain schizophrenia coding, time since the last standard survey, ownership change, staffing waivers, and Special Focus Facility candidate status.
CMS will send eligibility lists to states quarterly; a facility qualifies for six months unless a disqualifying event occurs. A state or CMS may still require the traditional process because of complaints or resident-safety concerns, and every nursing home remains subject to a standard survey at least every 15 months. CMS plans a Care Compare icon for September 30, but that public marker can lag the state's operational list. Neither is a compliance certificate or safe harbor.
The F756 chain did not get shorter
The memo does not rewrite the pharmacy-services rule or Appendix PP. Under 42 CFR § 483.45(c), a licensed pharmacist must review each resident's drug regimen at least monthly, including the medical chart. An identified irregularity requires a separate written report to the attending physician, medical director, and director of nursing that names at least the resident, drug, and irregularity.
The attending physician must document review and action; if the medication is unchanged, the record should contain the rationale. Facility policy must set time frames and the pharmacist's urgent-action path. Appendix PP also expects a signed, dated statement when no irregularity is found. Software can carry this chain, but ‘sent’ or ‘closed’ alone does not prove receipt, action, rationale, or follow-up.
The practical implication of a smaller sample
CMS does not tell pharmacists to document differently because the sample is smaller. The practical inference is simpler: a selected trail must make sense without oral history or detective work across an inbox, shared drive, pharmacy system, and facility chart.
That means preserving the resident context, specific irregularity, recipients, report date and route, response, rationale, current status, and next review point. The strongest record is concise enough to use and complete enough to reconstruct.
Run a six-link record test before September
Test one ordinary recommendation, one urgent irregularity, and one item closed with no medication change. Give the permitted records to a colleague who did not handle them. Fix each question the colleague must ask; never backfill facts that were not documented.
The RBS Procedure Guide was not public with the July memo, so pharmacy-specific survey mechanics should not be invented. This test cannot certify compliance or predict an outcome, but it can expose a weak routine record before a reviewer or covering consultant meets it under pressure.
- Context: Can a permitted reviewer see which chart, medication, indication, monitoring information, and resident circumstances informed the review?
- Finding: Is the irregularity or clinical question specific, dated, and distinguishable from a generic template?
- Route: Does the record show the required recipients and how the report was delivered, without treating delivery as verified unless it was?
- Response: Can the team find the physician's action—or the rationale for no medication change—in the appropriate record?
- Follow-up: Is an unresolved, deferred, or time-bound item still visible to the consultant and a covering pharmacist?
- Correction: If a report or status was changed, can the team distinguish the original record, the correction, who made it, and when?